BioCentury
ARTICLE | Clinical News

Cellular BioMedicine to test stem cell therapy in Chinese Phase II for knee osteoarthritis

February 15, 2019 6:54 PM UTC

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) said China's National Medical Products Administration (NMPA) approved an IND for a Phase II trial of AlloJoin to treat knee osteoarthritis.

The product is an allogeneic adipose-derived mesenchymal progenitor cell therapy...

BCIQ Company Profiles

AbelZeta Pharma Inc.